029 Group SE

Earnings Release • Oct 28, 2002

News Details

Ad-hoc | 28 October 2002 08:00

Rhein Biotech N.V. english

Rhein Biotech provides update: Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech provides update: – Strategic marketing alliance between Berna Biotech and Shire Pharmaceuticals – Exit from vaccine trade-goods business in Korea – Net income forecast for 2002 adjusted Rhein Biotech announced today that it will take part in a strategic marketing alliance between Berna Biotech and Shire Pharmaceuticals. Under the terms of the agreement Shire has obtained exclusive marketing rights in Europe for Rhein Biotech’s hepatitis B vaccine Hepavax-Gene. For more information on the broader strategic marketing alliance between Berna Biotech and Shire, we refer to the press release issued today by Berna Biotech (www.bernabiotech.com). Furthermore Rhein Biotech announced that it has made a strategic decision to exit the low-margin vaccine trade-goods business in Korea as from October 1, 2002. This will impact Rhein Biotech’s stand-alone top line sales forecasts but will have little impact on net income. Sales of vaccine trade-goods accounted for around Euro 20 million in the first three quarters of 2002. The company also announced that mainly due to extraordinary re-structuring costs, it will not reach the net income level forecast (Euro 6-7 million) for 2002. end of ad-hoc-announcement (c)DGAP 28.10.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Berna Biotech AG (Swiss Exchange: BBIN) has acquired 92.2 percent of the Rhein Biotech share capital by means of a friendly takeover. Rhein Biotech is now a full member of the Berna Biotech Group. The integration of the two companies will create a leading player for innovation in vaccines. For further information please see the press release issued today by Berna Biotech ( http://www.bernabiotech.com ) Rhein Biotech N.V. Marcel Jacobs Communication Manager E: m.jacobs@rheinbiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 280800 Okt 02